{"id":"https://genegraph.clinicalgenome.org/r/400c8011-7663-4f57-8fa7-9a629f72d3a7v1.0","type":"EvidenceStrengthAssertion","dc:description":"*PPP2R1A* was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2015 (PMIDs: 25533962, 26168268). Individuals with *PPP2R1A* pathogenic variants present with developmental delay, intellectual disability, hypotonia, and language delay (PMIDs: 26168268, 33106617). Other common features include hypermobile joints, behavioral problems, epilepsy, and macrocephaly (PMIDs: 26168268, 33106617). Over 30 individuals with neurodevelopmental disorders and a *de novo* PPP2R1A missense variant have been reported in the literature (PMIDs: 26168268, 31531803, 31687265, 33106617). Only 10 probands are included in this curation because the maximum score for genetic evidence has been reached.\n \n*PPP2R1A* encodes the scaffolding Aα subunit of protein phosphatase type 2A (PP2A). The Aα subunit acts as a scaffolding molecule, coordinating the assembly of the catalytic C subunit and a variable regulatory B subunit to produce functionally diverse PP2A heterotrimers (PMID: 9989501). *PPP2R1A* variants cluster in the HEAT repeat and intrarepeat region of the protein (PMID: 33106617). The reported *de novo* recurrent and clustered missense variants that reduce catalytic C subunit binding, as well as variants that decrease PP2A activity but not catalytic subunit binding, suggest that *PPP2R1A* variants cause PP2A dysfunctions via both dominant-negative and haploinsufficiency mechanisms (PMIDs: 26168268, 33106617). The gene-disease relationship is also supported by experimental evidence, including protein interaction and biochemical function (PMIDs: 26168268, 33106617).\n \nIn summary, there is definitive evidence to support the relationship between *PPP2R1A* and autosomal dominant complex neurodevelopmental disorder. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on November 16, 2022 (SOP Version 9).\n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/400c8011-7663-4f57-8fa7-9a629f72d3a7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2022-11-16T17:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2022-12-20T15:14:07.521Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53d490e9-0ba9-4e7d-a2fc-eea08eebe9ee","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/27e9083f-bfa9-40e3-b3c6-9634759e941b","type":"Finding","dc:description":"The wild type Aα subunit, encoded by PPP2R1A, forms a functional PP2A holoenzyme, thereby regulating the PP2A phosphatase activity. \n\nSimilarly, PPP2RD encodes for the B subunit of protein phosphatase 2A (PP2A). The subunit encoded by PPP2RD is required for PP2A holoenzyme formation and PP2A phosphatase activity.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26168268","rdfs:label":"Aα subunit is involved in PP2A biochemical function","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/577bac62-25a6-4f91-b327-7082023904c8","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/11253f8f-d392-432c-8ca4-7125e4bfa1e3","type":"Finding","dc:description":"The protein encoded by PPPR1A, Aα subunit interacts with B56δ regulatory subunit encoded by the PPP2R5D gene. De novo pathogenic variants in PPP2R5D are associated with intellectual disability (PMID: 26576547).\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","rdfs:label":"B56δ-Aα subunits interaction","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/1aae8155-7cb1-44ee-9cee-17bb22e6a0ad_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce03e838-9c22-4704-af8c-9fce0c09f48c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ce03e838-9c22-4704-af8c-9fce0c09f48c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro assays showed that the R258S variant lost binding to the C subunit and abolished PP2A phosphatase activity","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ce03e838-9c22-4704-af8c-9fce0c09f48c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/ee3c3e42-5289-4ea3-81a0-8fab3ac96766","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.772C>A (p.Arg258Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407185416"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9ee4c0c3-0f34-48c6-9f88-a6993eadb181","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9ee4c0c3-0f34-48c6-9f88-a6993eadb181_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro binding assay showed that the F141I variant lost binding to B subunit families, abolishing PP2A holoenzyme formation. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/9ee4c0c3-0f34-48c6-9f88-a6993eadb181_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/7e2b0bca-d422-4299-ab5d-42b0754de7b7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.421T>A (p.Phe141Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407182702"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/faa46c3b-d57d-4da6-8e0d-8c1ca6fe05e6","type":"EvidenceLine","dc:description":"Additional 0.5 points were awarded because this variant is recurrent. The variant has been observed in three individuals in this study. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/faa46c3b-d57d-4da6-8e0d-8c1ca6fe05e6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro binding assay showed that the M180V variant lost binding to B subunit families, abolishing PP2A holoenzyme formation. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/faa46c3b-d57d-4da6-8e0d-8c1ca6fe05e6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/c10526cd-8d87-4e0e-b684-dbc6587867a3","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.538A>G (p.Met180Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407183521"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3c40be8f-e255-4b3c-9e54-46dc6e08aad9","type":"EvidenceLine","dc:description":"Additional 0.5 points were awarded because this variant is recurrent. The variant has been observed in three individuals in this study, and other individuals in other studies. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c40be8f-e255-4b3c-9e54-46dc6e08aad9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro cellular binding assays showed that mutant PPP2R1A failed to interact with the PP2A complex C subunit, affecting holoenzyme formation. \n\nIn vitro PP2A phosphatase assay with PP2R1A (A1a) mutant showed  PP2A showed decreased phosphatase activity for all Aα mutants compared with WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3c40be8f-e255-4b3c-9e54-46dc6e08aad9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26168268","allele":{"id":"https://genegraph.clinicalgenome.org/r/9271a468-484e-44cb-b346-270001fe2b53","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.544C>T (p.Arg182Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA199662"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/220064ea-84d6-47e6-9206-8a2536f3aa4a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/220064ea-84d6-47e6-9206-8a2536f3aa4a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro cellular binding assays showed that the R258H mutant showed reduced binding with the PP2A complex C subunit, affecting holoenzyme formation. \n\nIn vitro PP2A phosphatase assay with PP2R1A (A1a) mutant showed decreased phosphatase activity compared with WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/220064ea-84d6-47e6-9206-8a2536f3aa4a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26168268","allele":{"id":"https://genegraph.clinicalgenome.org/r/f2598dac-13e8-4ec6-b7cd-deb0ccdf2de2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.773G>A (p.Arg258His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA279323"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/ef5550b2-e9d6-4160-9d62-f4c496d6d3b1","type":"EvidenceLine","dc:description":"An additional 0.5 points was awarded because this variant is recurrent. The variant has been observed in 5 individuals in this study, and other individuals in other studies. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ef5550b2-e9d6-4160-9d62-f4c496d6d3b1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro binding assay showed that the M180T variant lost binding to B subunit families, abolishing PP2A holoenzyme formation. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/ef5550b2-e9d6-4160-9d62-f4c496d6d3b1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/ea3ddd8e-7ca9-4b2e-9fe4-d62bcffedb3a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.539T>C (p.Met180Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407183530"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/db085215-9e16-4d0e-bffa-bec69e50e48e","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/db085215-9e16-4d0e-bffa-bec69e50e48e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro assays showed that the T178N variant lost binding to the C subunit and abolished PP2A phosphatase activity","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/db085215-9e16-4d0e-bffa-bec69e50e48e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/1715a1e1-7752-45ab-91ab-50dd54489960","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.533C>A (p.Thr178Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407183500"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/155c9f9a-01fa-456c-afca-f732d325cef1","type":"EvidenceLine","dc:description":"Additional 0.5 points were awarded because this variant is recurrent. The variant has been observed in three individuals in this study. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/155c9f9a-01fa-456c-afca-f732d325cef1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro binding assays showed that the S219L variant lost binding to both B and C subunits, abolishing PP2A holoenzyme formation.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/155c9f9a-01fa-456c-afca-f732d325cef1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/d5bf9f94-bd62-43bd-9948-9aaea7b2726f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.656C>T (p.Ser219Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407184277"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/7b55a803-f16e-4561-8e49-f1c955cfee5d","type":"EvidenceLine","dc:description":"Additional 0.5 points were awarded because this variant is recurrent. The variant has been observed in 4 individuals in this study. ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7b55a803-f16e-4561-8e49-f1c955cfee5d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro binding assay showed that the V220M variant lost binding to B subunit families, abolishing PP2A holoenzyme formation. ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/7b55a803-f16e-4561-8e49-f1c955cfee5d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33106617","allele":{"id":"https://genegraph.clinicalgenome.org/r/a01c4e03-0240-4e95-9dbc-ef3ebc2158c1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.658G>A (p.Val220Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA407184282"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/0f5cb710-8acb-4624-a63a-70922516ca5b","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f5cb710-8acb-4624-a63a-70922516ca5b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In vitro cellular binding assays showed that mutant PPP2R1A failed to interact with the PP2A complex C subunit, affecting holoenzyme formation. \n\nIn vitro PP2A phosphatase assay with PP2R1A (A1a) mutant showed  PP2A showed decreased phosphatase activity for all Aα mutants compared with WT.","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/0f5cb710-8acb-4624-a63a-70922516ca5b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26168268","allele":{"id":"https://genegraph.clinicalgenome.org/r/4fb33bc8-05a0-4d01-9f1a-bc55a32fd1ed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014225.6(PPP2R1A):c.536C>T (p.Pro179Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA199664"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":5519,"specifiedBy":"GeneValidityCriteria9","strengthScore":13,"subject":{"id":"https://genegraph.clinicalgenome.org/r/Lcm1xAqteK4","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:9302","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_1aae8155-7cb1-44ee-9cee-17bb22e6a0ad-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}